In a report published Tuesday, Jefferies analyst Anthony Petrone initiated coverage on Mallinckrodt PLC MNK with a Buy rating and $60.00 price target.
In the report, Jefferies noted, “Mallinckrodt is uniquely positioned in a consolidating Specialty Pharma industry having three attractive attributes: 1) Potential long duration assets in Xartemis XR and MNK-155, 2) Room for margin expansion post spin; and 3) Tax leverage from its Irish domicile. We see the combination as supporting accelerating earnings over the next three years with potential optionality from M&A and licensing. We rate shares Buy with a $60 PT.”
Mallinckrodt PLC closed on Monday at $50.60.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in